ID   NoGFP-CD16.NK92
AC   CVCL_V429
DR   ATCC; PTA-6967
DR   Wikidata; Q54930889
RX   Patent=US9181322;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6967.
CC   Population: Caucasian.
CC   Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val).
CC   Discontinued: ATCC; PTA-6967; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
ST   Source(s): ATCC=PTA-6967
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 02-05-24; Version: 13
//
RX   Patent=US9181322;
RA   Campbell K.S.;
RT   "Genetically modified human natural killer cell lines.";
RL   Patent number US9181322, 10-Nov-2015.
//